TABLE 2.
Control Subjects | Untreated FD | Treated FD | |
---|---|---|---|
miR-1 | 9.81 ± 0.926 | 4.62 ± 0.568* | 7.42 ± 0.872** |
miR-181c | 9.49 ± 0.887 | 18.98 ± 2.167* | 18.89 ± 1.920* |
miR-338 | 9.86 ± 1.436 | 19.18 ± 1.586* | 23.07 ± 1.966* |
miR-130a | 6.81 ± 0.872 | 14.42 ± 1.802* | 15.06 ± 1.563* |
miR-210 | 9.05 ± 0.788 | 18.86 ± 2.216* | 14.88 ± 1.457* |
miR-15a | 10.29 ± 0.986 | 20.23 ± 2.021* | 19.49 ± 1.954* |
miR-21-5-p | 8.51 ± 1.208 | 18.97 ± 1.871* | 16.21 ± 1.777* |
miR-696 | 7.67 ± 1.123 | 17.92 ± 2.152* | 18.80 ± 2.040* |
miR-17 | 9.44 ± 1.025 | 19.06 ± 2.258* | 20.21 ± 2.069* |
miR-486 | 6.10 ± 1.256 | 20.48 ± 2.271* | 18.02 ± 2.250* |
miR-23b | 13.41 ± 1.116 | 22.82 ± 2.476* | 19.54 ± 1.769* |
*P < 0.05 versus controls.
**P < 0.05 versus untreated.